Background
To determine outcomes in breast cancer patients treated with neoadjuvant chemotherapy.
Methods
72 consecutive patients receiving neoadjuvant chemotherapy for breast cancer were enrolled.
Results
Mastectomy was avoided in 46% of patients and 42% converted to negative nodes after neoadjuvant chemotherapy. Thirteen patients (18%) achieved a pathologic complete response (pCR), which was associated with the ER−/Her2− subtype (58%), and was significantly less likely to occur in the ER+/Her2− subtype (2%), p<0.01. Patients with ER+/Her2+ subtype were most likely to have no response or progression (NR/P) during chemotherapy compared to ER−/Her2− subtype (50% vs 0%, p=0.01). The five-year survival for patients achieving a pCR was 100% compared to 74% in the partial response group and 48% in the NR/P group (p=0.01).
Conclusions
Neoadjuvant chemotherapy for patients with advanced breast cancer provided prognostic information, allowed evaluation of response to chemotherapy, decreased mastectomy rate and potentially reduced the need for axillary node dissection.